-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166

Benzinga·08/12/2026 15:53:11
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $180 to $166.